GlassScriptPhysician profile
Thomas Moriarity
NPI 1669443065
$15,662.47
in general payments reported to CMS, 2019-2025
65 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $1,303 · 2021: $1,841 · 2022: $1,649 · 2023: $4,202 · 2024: $3,567 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,516 · Travel and Lodging: $3,790 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,515.77 |
| Travel and Lodging | $3,790.21 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $2,604.18 | 2024 | |
| Boehringer Ingelheim International Gmbh | $2,282.03 | 2023 | |
| Amgen INC. | $1,446.10 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,024.12 | 2019-2025 | |
| Abbvie INC. | $763.84 | 2021-2025 | |
| Novo Nordisk INC | $751.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $713.13 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $601.10 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Pfizer INC. | $565.44 | 2019-2025 | |
| Esperion Therapeutics, INC. | $555.56 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $546.09 | 2019-2025 | Airsupra, Breztri |
| Supernus Pharmaceuticals, INC. | $406.12 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $405.76 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.81 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $317.32 | 2021-2023 |
Show all 57 companies
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Moriarity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.